Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.

This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.

The Scientist goes to court for a CRISPR patent interference case at the US Patent and Trademark Office.

Documents suggest Feng Zhang started working on CRISPR before Jennifer Doudna’s group published; researchers call for CRISPR technology to be shared openly

This week’s CRISPR patent hearing took a deep dive into the science of moving the gene-editing technology from prokaryotes to eukaryotic systems.

Tuesday morning, the US Patent and Trademark Office will hear oral arguments from the two parties that claim to have been the first to use CRISPR-Cas9 gene editing technology in eukaryotic cells.

Roger Tsien dies; the CRISPR patent dispute you’ve never heard of; immunotherapy for Alzheimer’s; Tasmanian devils developing resistance to transmissible cancer

The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

A former researcher at the Broad Institute has suggested the University of California, Berkeley, team deserves credit for inventing the gene-editing technique.